At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
MLTX MoonLake Immunotherapeutics
Pre-Mkt 10-12 06:42:03 EDT
10.82
+0.24
+2.27%
盘前10.73
-0.09-0.83%
04:01 EDT
High11.09Low10.40Vol2.01M
Open10.58D1 Closing10.58Amplitude6.52%
Mkt Cap920.85MTradable Cap600.17MTotal Shares85.11M
T/O21.76MT/O Rate3.63%Tradable Shares55.47M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

MoonLake Immunotherapeutics Could Win FDA Approval for Sonelokimab by Year-End 2027, Wedbush Says
MT Newswires Live  ·  10-05
MoonLake Immunotherapeutics Could Win FDA Approval for Sonelokimab by Year-End 2027, Wedbush Says
MoonLake Immunotherap Price Target Maintained with a $50.00/Share by HC Wainwright & Co.
Dow Jones  ·  10-05
MoonLake Immunotherap Price Target Maintained with a $50.00/Share by HC Wainwright & Co.
MoonLake Immunotherapeutics - Submits Bla to FDA for Sonelokimab to Treat Hidradenitis Suppurativa - SEC Filing
THOMSON REUTERS  ·  10-01
MoonLake Immunotherapeutics - Submits Bla to FDA for Sonelokimab to Treat Hidradenitis Suppurativa - SEC Filing
MoonLake Submits FDA BLA for Sonelokimab in Hidradenitis Suppurativa
Reuters  ·  10-01
MoonLake Submits FDA BLA for Sonelokimab in Hidradenitis Suppurativa
H.C. Wainwright Reaffirms Their Buy Rating on MoonLake Immunotherapeutics (MLTX)
TIPRANKS  ·  08-13
H.C. Wainwright Reaffirms Their Buy Rating on MoonLake Immunotherapeutics (MLTX)
MoonLake Immunotherapeutics : H.c. Wainwright Raises Target Price to $50 from $45
THOMSON REUTERS  ·  08-13
MoonLake Immunotherapeutics : H.c. Wainwright Raises Target Price to $50 from $45
MoonLake Immunotherapeutics (MLTX) Receives a Hold from RBC Capital
TIPRANKS  ·  08-12
MoonLake Immunotherapeutics (MLTX) Receives a Hold from RBC Capital
Guggenheim Reaffirms Their Buy Rating on MoonLake Immunotherapeutics (MLTX)
TIPRANKS  ·  08-11
Guggenheim Reaffirms Their Buy Rating on MoonLake Immunotherapeutics (MLTX)
MoonLake Immunotherapeutics: Files for Mixed Shelf Offering, Size not Disclosed - SEC Filing
THOMSON REUTERS  ·  08-11
MoonLake Immunotherapeutics: Files for Mixed Shelf Offering, Size not Disclosed - SEC Filing
MoonLake Immunotherapeutics Reports Results for the Quarter Ended June 30 - Earnings Summary
Reuters  ·  08-10
MoonLake Immunotherapeutics Reports Results for the Quarter Ended June 30 - Earnings Summary
MoonLake Immunotherapeutics Q2 Loss Narrows, Phase 3 PsA Trial Meets Clinical Goals
MT Newswires Live  ·  08-10
MoonLake Immunotherapeutics Q2 Loss Narrows, Phase 3 PsA Trial Meets Clinical Goals
MoonLake's Psoriatic Arthritis Drug Meets Key Goals in Late-Stage Trial
Reuters  ·  08-10
MoonLake's Psoriatic Arthritis Drug Meets Key Goals in Late-Stage Trial
MoonLake Q2 FY26 Net Loss Widens 10.3% to $61.81 Million
Reuters  ·  08-10
MoonLake Q2 FY26 Net Loss Widens 10.3% to $61.81 Million
MoonLake says Phase 3 IZAR-1 trial met all clinical endpoints at Week 16
TIPRANKS  ·  08-10
MoonLake says Phase 3 IZAR-1 trial met all clinical endpoints at Week 16
MoonLake Q2 EPS $(0.84) Beats $(0.93) Estimate
Benzinga Earnings  ·  08-10
MoonLake Q2 EPS $(0.84) Beats $(0.93) Estimate
Switzerland's MoonLake Q2 Net Loss Narrows as Expenses Fall
Reuters  ·  08-10
Switzerland's MoonLake Q2 Net Loss Narrows as Expenses Fall
MoonLake Immunotherapeutics - Blinded Safety Analysis Shows no New Safety Signals for Sonelokimab
THOMSON REUTERS  ·  08-10
MoonLake Immunotherapeutics - Blinded Safety Analysis Shows no New Safety Signals for Sonelokimab
MoonLake Immunotherapeutics - Acr50 Primary Endpoint Met with 42.1% Response for Sonelokimab 60 Mg
THOMSON REUTERS  ·  08-10
MoonLake Immunotherapeutics - Acr50 Primary Endpoint Met with 42.1% Response for Sonelokimab 60 Mg
MoonLake Immunotherapeutics - Phase 3 Izar-1 Trial Meets All Clinical Endpoints at Week 16 for 60 Mg Sonelokimab
THOMSON REUTERS  ·  08-10
MoonLake Immunotherapeutics - Phase 3 Izar-1 Trial Meets All Clinical Endpoints at Week 16 for 60 Mg Sonelokimab
MoonLake Immunotherapeutics Q2 EPS USD -0.84
THOMSON REUTERS  ·  08-10
MoonLake Immunotherapeutics Q2 EPS USD -0.84

Introduction

Company Name.
MoonLake Immunotherapeutics
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or axial spondyloarthritis. MoonLake Immunotherapeutics was incorporated in 2021 and is headquartered in Zug, Switzerland.
Issue price:
--